Radient Pharmaceuticals signs agreement with Phu Gia Trading for Onko-Sure

http://www.tradingmarkets.com/

via CAAI

Posted on: Tue, 28 Sep 2010

Sep 28, 2010 (Datamonitor Financial Deals Tracker via COMTEX) --

Radient Pharmaceuticals

Corporation (RPC), through its subsidiary AMDL Diagnostics, Inc., has entered into an exclusive five-year full-service distribution agreement with Phu Gia Trading Co., Ltd. to expand Radient's Onko-Sure(TM) IVD cancer test into Vietnam, Laos and Cambodia healthcare markets.

Phu Gia is a Vietnam-based general trading company, RPC is an integrated pharmaceutical company, and AMDL is engaged in the research, development, manufacture and sales of Onko-Sure.

Onko-Sure is an in vitro diagnostic test that enables physicians and their patients to monitor and detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP).

Under this agreement, Phu Gia has agreed to purchase a minimum of 2,425 Onko-Sure kits over the duration of the agreement. Phu Gia will represent RPC while obtaining regulatory clearances and providing marketing, sales, and distribution services for Onko-Sure in diagnostic centers and clinical labs throughout the designated territory.

The marketing, sales and distribution services include, developing product localization strategies, representing RPC and its Onko-Sure IVD cancer test at healthcare conferences and events and ensuring all product marketing materials are available in local languages.